At Creative Diagnostics, our B cell sorting & sequencing platform solves challenges by integrating advanced cell sorting with single-cell RNA sequencing (scRNA-seq) and immune receptor repertoire sequencing (IR-SEQ) in one workflow. Our platform serves researchers focused on vaccine development, autoimmunity research and antibody discovery by providing unmatched insights into B cell diversity alongside clonal evolution and functional states. Creative Diagnostics offers a full-featured platform for B cell sorting and sequencing that meets your scientific research requirements.
The B Cell Sorting & Sequencing Platform represents state-of-the-art technology capable of high-throughput B cell isolation, characterization and sequencing from different biological samples. Researchers gain access to a powerful discovery tool through the integration of advanced cell sorting with next-generation sequencing (NGS) for antibody research and cancer studies. Through the combined use of fluorescent-activated cell sorting (FACS) and single-cell RNA sequencing (scRNA-seq), this platform accomplishes precise B cell separation using surface markers and functional properties and conducts deep sequencing of their transcriptomes to discover novel antibody repertoires and immune responses.
The B Cell Sorting & Sequencing Platform at Creative Diagnostics combines cutting-edge technologies to address the complexities of B cell research. Below are the core features that distinguish it as a powerful tool for researchers:
The platform supports researchers in finding antigen-specific B cell clones along with neutralizing antibody sequences which are essential to developing vaccines. Vaccine effectiveness evaluation and booster optimization becomes possible when researchers monitor B cell clonal evolution through B cell receptor (BCR) repertoire analysis and clonal expansion patterns in vaccinated samples.
B Cell Sorting & Sequencing Platform helps autoimmune disease research by identifying dysfunctional B cell subsets and harmful antibody clones through mapping clonally expanded B cells that generate autoantibodies to develop specific immunosuppressive treatments or diagnostic tests.
The platform accelerates therapeutic antibody development by extracting naive or memory B cells from human and animal samples and sequencing their immunoglobulin loci to identify new antibody candidates. Researchers integrate scRNA-seq with functional assays to relate B cell phenotypes such as plasma cell and memory B cell to antibody specificity and affinity for the rational design of bispecific or humanized antibodies.
Creative Diagnostics offers professional B Cell Sorting & Sequencing Platform, designed to empower researchers with cutting-edge technologies for precise B cell analysis and characterization, which provides researchers with cutting-edge technology for precise B cell analysis and characterization.
The B Cell Sorting & Sequencing Platform delivers sophisticated cell sorting capabilities through the application of modern flow cytometers and FACS systems. These instruments provide accurate separation of B cells from complex cell mixtures by targeting surface markers along with size and additional phenotypic traits. We can employ multi-color immunofluorescence labeling combined with high-speed sorting using up to 30 fluorescent parameters to achieve high-quality isolation of B cells with high purity and yield.
The platform offers complete single-cell RNA sequencing (scRNA-seq) services for examining the transcriptomes of each individual B cell. Researchers use this system to analyze gene expression patterns while identifying rare B cell subsets and detecting clonal expansions or mutations. Researchers utilize high-throughput sequencing platforms to perform sequencing which produces both deep coverage and accurate data.
The antibody development and production platform integrated access to multiple antibody development services including hybridoma technology and B cell cloning which leads to monoclonal antibody production. High-affinity and high-specificity antibodies can be generated directly from isolated and sequenced B cells. The platform enables researchers to create specialized ELISA kits which detect and validate antibodies for both research purposes and therapeutic use.
Biological samples like spleen or lymph node tissues are prepared as the first step in this process. The biological samples undergo immunization with the target antigen to stimulate a B cell response. The immunization protocol is designed to enhance B cell activation to achieve maximum antibody production.
Researchers isolate B cells from immunized tissue samples through collagenase digestion followed by FACS sorting. Fluorescent labels on CD19, CD20, and CD22 surface markers guide the sorting process to achieve high-purity B cell isolation. Researchers increase the viability and singlet status of sorted B cells to limit contamination and enhance sequencing quality.
The isolated B cells undergo automated library preparation for scRNA-seq processing. Researchers use high-throughput sequencing platform to sequence libraries and obtain complete transcriptomic data. Bioinformatics tools can be used to detect genetic variants and perform gene expression analysis.
Specialized software processes sequencing data to pinpoint B cell subsets and clonal expansions along with potential therapeutic targets. Researchers use the data to direct monoclonal antibody development by employing hybridoma technology and B cell cloning techniques. Researchers perform ELISA and additional immunoassays to verify the specificity and binding strength of the finalized antibodies.
Figure 5. The graph illustrates the binding specificity of antibodies derived from sorted B cells across varying concentrations, demonstrating the platform's ability to identify high-affinity antibody clones targeting specific epitope
The system operates effectively using sample sizes that reach as few as 100,000 cells. The sequencing results reach their best quality when researchers use a minimum of one million cells.
The platform functions with human samples such as blood as well as spleen and lymph node tissues. The platform serves well for non-human primate specimens and additional animal model types.
Research applications make up the main purpose for which the platform was designed, including both preclinical and translational study uses. The platform does not support clinical diagnosis or treatment applications.
The B Cell Sorting & Sequencing Platform functions as both a strong and flexible instrument for scientific studies of immune systems and antibody creation. The platform uses sophisticated cell sorting and sequencing technologies to allow researchers to study B cell biology intricacies and create new therapeutic antibodies. The platform serves as a crucial research instrument in immunology and oncology because of its flexible nature and ability to scale while integrating various service options. Contact us for more service information.
